These novel therapies , Semaglutide , represent a significant advancement in addressing obesity and potentially other conditions . These drugs are grouped as GLP-1 pathway agonists , signifying these substances to replicate the body's GLP-1 hormone , enhancing glucose secretion and lowering appet